Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2019 | 762 | 3.300 |
Why?
|
| Autophagy | 13 | 2018 | 55 | 2.430 |
Why?
|
| Heat-Shock Proteins | 6 | 2019 | 38 | 2.210 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2018 | 106 | 2.090 |
Why?
|
| Estrogen Receptor Modulators | 6 | 2017 | 26 | 1.750 |
Why?
|
| Unfolded Protein Response | 8 | 2019 | 15 | 1.610 |
Why?
|
| Diet, Mediterranean | 2 | 2019 | 31 | 1.160 |
Why?
|
| Drug Discovery | 2 | 2015 | 38 | 0.900 |
Why?
|
| Apoptosis | 9 | 2018 | 375 | 0.840 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 595 | 0.720 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 14 | 0.720 |
Why?
|
| Tamoxifen | 3 | 2017 | 59 | 0.660 |
Why?
|
| Neoplasms | 2 | 2019 | 754 | 0.650 |
Why?
|
| Animals | 22 | 2021 | 8199 | 0.640 |
Why?
|
| Bacteria | 1 | 2019 | 54 | 0.590 |
Why?
|
| Estrogen Antagonists | 3 | 2014 | 16 | 0.550 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 50 | 0.520 |
Why?
|
| Female | 23 | 2021 | 19945 | 0.520 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 163 | 0.510 |
Why?
|
| Estradiol | 2 | 2014 | 139 | 0.500 |
Why?
|
| Mice | 11 | 2019 | 2571 | 0.490 |
Why?
|
| Signal Transduction | 7 | 2019 | 727 | 0.470 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 108 | 0.470 |
Why?
|
| Humans | 26 | 2021 | 32282 | 0.470 |
Why?
|
| Breast | 1 | 2015 | 63 | 0.440 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 104 | 0.440 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 11 | 0.420 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 33 | 0.370 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2017 | 27 | 0.370 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 7 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 31 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 164 | 0.290 |
Why?
|
| Angiotensin I | 1 | 2010 | 237 | 0.290 |
Why?
|
| Peptide Fragments | 2 | 2011 | 415 | 0.280 |
Why?
|
| Mice, Nude | 3 | 2014 | 285 | 0.280 |
Why?
|
| Blotting, Western | 3 | 2014 | 299 | 0.280 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 363 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 729 | 0.260 |
Why?
|
| Mammary Glands, Animal | 2 | 2019 | 69 | 0.260 |
Why?
|
| Cell Proliferation | 4 | 2018 | 603 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 40 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 114 | 0.210 |
Why?
|
| Diet | 3 | 2021 | 383 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 47 | 0.190 |
Why?
|
| Bacteroides | 1 | 2021 | 8 | 0.170 |
Why?
|
| Prevotella | 1 | 2021 | 8 | 0.170 |
Why?
|
| Lactobacillus | 1 | 2021 | 12 | 0.170 |
Why?
|
| Feces | 1 | 2021 | 41 | 0.170 |
Why?
|
| Primates | 1 | 2021 | 128 | 0.160 |
Why?
|
| Endoribonucleases | 1 | 2019 | 5 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 6 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 196 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 897 | 0.150 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2019 | 49 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 63 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 140 | 0.140 |
Why?
|
| Leptin | 1 | 2019 | 61 | 0.140 |
Why?
|
| Obesity | 3 | 2021 | 1111 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 222 | 0.140 |
Why?
|
| Haplorhini | 1 | 2018 | 75 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2018 | 52 | 0.130 |
Why?
|
| Colistin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Soy Foods | 1 | 2017 | 8 | 0.130 |
Why?
|
| Genistein | 1 | 2017 | 17 | 0.130 |
Why?
|
| Phytoestrogens | 1 | 2017 | 25 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 40 | 0.130 |
Why?
|
| Ethinyl Estradiol | 1 | 2016 | 9 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2015 | 139 | 0.120 |
Why?
|
| Social Isolation | 1 | 2016 | 41 | 0.120 |
Why?
|
| Metabolomics | 1 | 2016 | 63 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2016 | 82 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2016 | 100 | 0.120 |
Why?
|
| Mitochondria | 1 | 2018 | 211 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 18 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 90 | 0.120 |
Why?
|
| Rats | 3 | 2017 | 1895 | 0.110 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 7 | 0.110 |
Why?
|
| Glutamine | 1 | 2014 | 10 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 29 | 0.110 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 74 | 0.100 |
Why?
|
| Aromatase Inhibitors | 1 | 2014 | 8 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2014 | 250 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 184 | 0.100 |
Why?
|
| Glucose | 1 | 2014 | 160 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 381 | 0.100 |
Why?
|
| Premenopause | 1 | 2014 | 53 | 0.100 |
Why?
|
| Ovary | 1 | 2014 | 66 | 0.100 |
Why?
|
| Estrogens | 1 | 2014 | 194 | 0.100 |
Why?
|
| Cathepsin D | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cathepsin L | 1 | 2013 | 1 | 0.100 |
Why?
|
| Burns | 1 | 2014 | 102 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 443 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 185 | 0.100 |
Why?
|
| Macrophages | 1 | 2014 | 207 | 0.090 |
Why?
|
| Pyrroles | 1 | 2013 | 59 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 255 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 212 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2014 | 461 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3626 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 92 | 0.090 |
Why?
|
| Angiotensins | 1 | 2011 | 42 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 43 | 0.080 |
Why?
|
| Fibronectins | 1 | 2010 | 39 | 0.080 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 95 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 408 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 63 | 0.080 |
Why?
|
| Fibrosis | 1 | 2010 | 126 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 173 | 0.080 |
Why?
|
| Adult | 1 | 2021 | 9259 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 423 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2017 | 5 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2015 | 65 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 38 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 792 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2015 | 243 | 0.050 |
Why?
|
| Adipokines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 38 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2019 | 23 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 7 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 132 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 37 | 0.030 |
Why?
|
| Thiazoles | 1 | 2018 | 36 | 0.030 |
Why?
|
| Pyridines | 1 | 2018 | 79 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 180 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 12 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 36 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 50 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 34 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 116 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2016 | 10 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2016 | 7 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 22 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 18 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2017 | 88 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 45 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 45 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 43 | 0.030 |
Why?
|
| Isoflavones | 1 | 2017 | 103 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 228 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 320 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 83 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 285 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 257 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 863 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 258 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 237 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 144 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 346 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1083 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 251 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 217 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 75 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 34 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 25 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 193 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 288 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 961 | 0.020 |
Why?
|
| Phagosomes | 1 | 2013 | 6 | 0.020 |
Why?
|
| Lysosomes | 1 | 2013 | 10 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 187 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 32 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 229 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 69 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 109 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 545 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3934 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4072 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3416 | 0.010 |
Why?
|